| Symbol | Name | Last Close | Mkt Cap | DailyStocks' Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
|
Vote Now! Wednesday’s Close |
|---|---|---|---|---|---|
| SNY | Sanofi | $43.75 | $109.14B | N/A |
All the 2020 Pre-JPM News Healthcare Investors Need to Know
https://www.fool.com/investing/2020/01/11/all-the-2020-pre-jpm-news-healthcare-investors-nee.aspx?source=iedfolrf0000001
Jan 11, 2020 - The Super Bowl of healthcare kicked off early for these companies.
0
3 Pharma & Biotech Pipeline Areas to Keep an Eye on in 2020
http://www.zacks.com/stock/news/707821/3-pharma-biotech-pipeline-areas-to-keep-an-eye-on-in-2020?cid=CS-ZC-FT-analyst_blog|industry_focus-707821
Jan 08, 2020 - Here we present three non-cancer therapeutic areas wherein pipeline developments are expected to garner a lot of interest in 2020.
0
Top Stock Reports for JPMorgan, Sanofi & General Electric
http://www.zacks.com/research-daily/706515/top-stock-reports-for-jpmorgan-sanofi-general-electric?cid=CS-ZC-FT-research_daily-706515
Jan 07, 2020 - Top Stock Reports for JPMorgan, Sanofi & General Electric
0
Amicus Progresses on Pipeline Development Amid Competition
http://www.zacks.com/stock/news/700524/amicus-progresses-on-pipeline-development-amid-competition?cid=CS-ZC-FT-analyst_blog|zer_report_update-700524
Jan 03, 2020 - Amicus (FOLD) progresses with the development of its pipeline. However, the company faces substantial competition.
0
Sanofi Says Its $2.5 Billion Biotech Takeover Is Just the Beginning
https://www.fool.com/investing/2019/12/14/sanofi-says-its-25-billion-biotech-takeover-is-jus.aspx?source=iedfolrf0000001
Dec 14, 2019 - Sanofi has the perfect gift for investors: Investment in its most promising businesses with plans to keep growing the dividend.
0
Pharma Stock Roundup: MRK, SNY to Buy Cancer Firms, LLY Starts New Lung Cancer Study
http://www.zacks.com/stock/news/668756/pharma-stock-roundup-mrk-sny-to-buy-cancer-firms-lly-starts-new-lung-cancer-study?cid=CS-ZC-FT-analyst_blog|stock_roundup-668756
Dec 13, 2019 - This week two deals grab headlines in the pharma space. Merck (MRK) offers to buy ArQule for $2.7 billion while Sanofi (SNY) signs a definitive deal to purchase Synthorx for $2.5 billion
0
The Zacks Analyst Blog Highlights: Novartis, AbbVie, Sanofi, Pioneer Natural Resources and Aqua America
http://www.zacks.com/stock/news/667191/the-zacks-analyst-blog-highlights-novartis-abbvie-sanofi-pioneer-natural-resources-and-aqua-america?cid=CS-ZC-FT-press_releases-667191
Dec 12, 2019 - The Zacks Analyst Blog Highlights: Novartis, AbbVie, Sanofi, Pioneer Natural Resources and Aqua America
0
Top Research Reports for Novartis, AbbVie & Sanofi
http://www.zacks.com/research-daily/665423/top-research-reports-for-novartis-abbvie-sanofi?cid=CS-ZC-FT-research_daily-665423
Dec 11, 2019 - Top Research Reports for Novartis, AbbVie & Sanofi
0
Sanofi, Regeneron to Amend Agreement for Kevzara & Praulent
http://www.zacks.com/stock/news/665440/sanofi-regeneron-to-amend-agreement-for-kevzara-praulent?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-665440
Dec 11, 2019 - Sanofi (SNY) intends to amend its antibody collaboration with Regeneron related to Kevzara and Praulent into a royalty-based agreement. Agreement terms for Dupixent to remain intact.
0
Sanofi (SNY) Looks Good: Stock Adds 6.2% in Session
http://www.zacks.com/stock/news/665353/sanofi-sny-looks-good-stock-adds-62-in-session?cid=CS-ZC-FT-tale_of_the_tape|price_movement-665353
Dec 11, 2019 - Sanofi (SNY) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
0